Company profile
Catalyst Pharmaceuticals, Inc.
NASDAQ: CPRX · Healthcare · Biotechnology
#201 of 1,418 Healthcare companies by revenue66th-percentile growth
EA Score
83B+FH 91DQ 77GM 71SS 79
v0.1 · 65/100 weight · provisional
↑ operating margin, net margin · ↓ revenue growth (YoY), growth stability
Methodology →Revenue TTM
$597.0M
Rev growth YoY (TTM)
+11.7%
Net income (FY)
$214.3M
Employees
182
as of 2026-08-07
Market cap
$3.9B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$589.0M$589.0M2025
Net income$214.3M$214.3M2025
Operating income$257.8M$257.8M2025
Total assets$1.1B$1.1B2025
Liabilities$149.7M$149.7M2025
Equity$954.3M$954.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product Revenue Net100%
License And Other Revenue0%
By geography
Non-US100%
The read
What is Catalyst Pharmaceuticals, Inc.’s revenue?
Catalyst Pharmaceuticals, Inc. booked $589.0M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 36.4% net margin.
Peers · Healthcare
UFP Technologies, Inc.80B+Veradigm Inc.——Azenta, Inc.75B+Hinge Health, Inc.47DBioventus Inc.66BOrganogenesis Holdings Inc.65BNeighbors
Miami-Dade →Key facts
CEORichard John Daly
SectorHealthcare
IndustryBiotechnology
HeadquartersCoral Gables, FL
ExchangeNASDAQ: CPRX
Employees182
IPO date2006-11-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.